KYMERA THERAPEUTICS, INC. Proceeds from Issuance of Private Placement
KYMERA THERAPEUTICS, INC. (KYMR) reported Proceeds from Issuance of Private Placement of $13.50 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. proceeds from issuance of private placement for the quarter ending 2025-06-30 was $13.50M.
- KYMERA THERAPEUTICS, INC. proceeds from issuance of private placement for the quarter ending 2024-12-31 was -$23.00K.
- KYMERA THERAPEUTICS, INC. proceeds from issuance of private placement for the quarter ending 2024-09-30 was $0.00.
- KYMERA THERAPEUTICS, INC. proceeds from issuance of private placement for the quarter ending 2024-06-30 was $0.00.
- KYMERA THERAPEUTICS, INC. proceeds from issuance of private placement for fiscal 2024 was $14.88M, a 7338.50% increase from fiscal 2023.
- KYMERA THERAPEUTICS, INC. proceeds from issuance of private placement for fiscal 2023 was $200.00K, a 14.94% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. proceeds from issuance of private placement for fiscal 2022 was $174.00K.
| Period end | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month | Proceeds from Issuance of Private Placement 12 month as first filed |
|---|---|---|---|---|---|
| 2025-06-30 | $13.50M 10-Q · filed 2026-08-05 | $13.50M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$23.00K derived: sum of 2 quarters · filed 2026-02-26 | -$23.00K derived: sum of 3 quarters · filed 2026-02-26 | $14.88M 10-K · filed 2026-02-26 | $200.00K 10-K · filed 2025-02-27 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $14.90M 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $14.90M 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | $14.90M 10-Q · filed 2025-05-09 | ||||
| 2023-12-31 | $200.00K 10-K · filed 2025-02-27 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $174.00K derived: sum of 2 quarters · filed 2025-02-27 | $174.00K 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $174.00K 10-Q · filed 2023-11-02 | $174.00K 10-Q · filed 2023-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |